A securities class action has been filed in the USDC — S.D.CA. against Maravai Lifesciences Holdings, Inc. (MRVI) (“Maravai” or the “Company”), on behalf of all persons or entities who purchased or otherwise acquired Maravai securities between August 7, 2024, and February 24, 2025, both dates inclusive (the “Class Period”).

Maravai is a life sciences company which provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide.

The Complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that:

(1) Maravai lacked adequate internal controls over financial reporting related to revenue recognition;

(2) as a result, the Company inaccurately recognized revenue on certain transactions during fiscal 2024;

(3) its goodwill was overstated; ; and

(4) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis, thereby harming investors.

If you purchased Maravai securities during the class period and would like to receive more information or join the action, please enter your contact information below for a FREE consultation and click “Submit Your Information”.

About Lowey Dannenberg

Lowey Dannenberg is a national firm representing institutional and individual investors, who suffered financial losses resulting from corporate fraud and malfeasance in violation of federal securities and antitrust laws. The firm has significant experience in prosecuting multi-million-dollar lawsuits and has previously recovered billions of dollars on behalf of investors.